Aki Prihti

Board member

Currently CEO of Aplagon, Aki Prihti is board member of Herantis since 2014 and one of the founding partners of Inveni Capital, a venture fund focused on life sciences. Aki Prihti has experience of Board positions in several Life Sciences growth companies; previously Chairman of Laurantis Pharma from 2010-2014, currently Chairman of Inveni Capital Ltd and Medeia Therapeutics Ltd. Prior to transitioning to life science venture capital he worked in the corporate finance arm of Salomon Brothers in London.